Daiichi Sankyo Co., Ltd. (Daiichi Sankyo) is a holding corporation that conducts pharmaceutical research, development, manufacturing, and marketing. The company provides a comprehensive range of prescription medications, over-the-counter (OTC) pharmaceuticals, vaccines, and other products. Its product range includes medications for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious disorders, as well as many types of cancer. Aside from cancer, the company's other research interests include uncommon diseases and immunological disorders.

Daiichi Sankyo's products are sold through its group companies and a large network of medical representatives. Its operations are spread over North America, South and Central America, Europe, and Asia. Daiichi Sankyo is based in Tokyo, Japan. The company owns Plexxikon in the United States, American Regent in the United States, U3 Pharma in Germany, and Ranbaxy Laboratories in India, which it just sold. Benicar (Olmesartan), an angiotensin II receptor antagonist and top-selling medicine in the United States, is manufactured by Daiichi Sankyo Co., Ltd. Olmesartan had global sales of 300.2 billion JPY in 2013.

Founded: 2005

Headquarters: Tokyo, Japan
Official website: https://www.daiichisankyo.com/

Visit website

Takeda Pharmaceutical has two main bases in Japan: one in Osaka and one in Tokyo. Its subsidiary in the United States is headquartered in Cambridge, Massachusetts, and all global operations outside of Japan and the United Kingdom are headquartered in Opfikon (Zurich), Switzerland. Takeda Pharmaceutical specializes in pharmaceutical drug discovery, development, manufacture, marketing, commercialization, import, and export. Fortune Magazine named Takeda Oncology Company one of the 100 greatest companies to work for in the United States in January 2012.

The company sells treatments for rare diseases, gastrointestinal disorders, oncology, neuroscience, vaccinations, and plasma-derived therapeutics. Takeda has facilities in, among other places, Japan, Argentina, Brazil, Mexico, the United States, Denmark, Norway, Europe, Poland, Russia, Spain, Switzerland, China, India, and Canada. It sells its products both directly and through a global network of wholesale distributors, retail chains, and other purchasing organizations. Takeda has collaborations with academic institutions, small biotech businesses, and large pharmaceutical corporations. It operates in the Americas, Europe, and Asia, among other places.

Founded: 1781
Headquarters: Tokyo, Japan
Official website: https://www.takeda.com/

Visit website

Chugai Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company. It is a subsidiary of Hoffmann-La Roche, which owned 62% of the firm as of June 30, 2014. Chugai focuses on biopharmaceutical and therapeutic antibody research, development, commercialization, production, import, and export. Furthermore, as a competitive advantage, the Japanese pharmaceutical company promotes its antibody engineering technology, personalized healthcare, and enhanced patient-centric solutions. Chugai has dominated the Japanese cancer market for over a decade and is presently developing treatments for bone and joint illnesses as well as renal ailments.

The company provides products for the treatment of a variety of therapeutic areas, including cancer, bone and joint illnesses, renal diseases, immunological disorders, and infectious diseases, among others. It also provides medications to help with kidney, liver, and other organ transplants. It also has a number of product candidates in the pipeline. The company sells pharmaceutical items in North America, Europe, and Asia through its network of subsidiaries.

Founded: 1943
Headquarters: Tokyo, Japan
Official website: https://www.chugai-pharm.co.jp/

Visit website

Astellas Pharma, founded in Osaka in 1923 and later headquartered in Tokyo, has a robust oncology product pipeline. Astellas Pharma Inc. is a pharmaceutical company that discovers, develops, manufactures, and commercializes a wide range of medications. Immunosuppressants, as well as therapies for prostate cancer, acute myeloid leukemia, and overactive bladder, are among the company's primary licensed drugs. Cell therapy for vision treatment, products for allergies and autoimmune illnesses, genetic regulation to advance gene therapy, and mitochondrial replacement therapy are its current top research priority areas.

The company's product portfolio includes marketed products for the treatment of urological disorders, cancer, nephrology, infectious diseases, metabolic diseases, immunodeficiency diseases, and transplantation. Its pipeline includes therapeutic candidates for the treatment of urothelial cancer, gastric cancer, gastroesophageal junction cancer, anemia associated with chronic kidney disease (CKD) in dialysis patients, rheumatoid arthritis in non-dialysis patients, and acute myeloid leukemia (AML). Through a network of subsidiaries and affiliates, it operates in the Americas, Australia, Europe, Asia, and Oceania. The headquarters of Astellas are in Tokyo, Japan.

Founded: 2005
Headquarters: Tokyo, Japan
Official website: https://www.astellas.com/en/

Visit website

Otsuka Holdings Co., Ltd. (Otsuka) is a holding company that operates several businesses through its subsidiaries, including medicines, nutraceuticals, consumer items, and others. Otsuka Holdings Co. Ltd., OPC's parent company, debuted on the Tokyo Stock Exchange on December 15, 2010, with an initial public offering. At the time, Otsuka Holdings was Japan's No. 2 medicine maker by revenue, trailing industry leader Takeda Pharmaceutical Company. The IPO was the largest for a pharmaceutical business at the time, with a valuation of $2.4 billion.

Its primary focus is on the development, manufacture, and distribution of medications for the treatment of cancer, cardiovascular illness, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological issues, and allergies. Pharmaceuticals, cosmetics, functional foods and beverages, alcoholic beverages, fine chemicals, electronic equipment, functional chemicals, medical devices, and OTC items are all part of the company's product line. Its products are sold in North America, Europe, and Asia. Otsuka's headquarters are in Tokyo's Chiyoda-ku.

Founded: 1921

Headquarters: Tokyo, Japan

Official website: https://www.otsuka.com/en/

Visit website

Eisai ranks 6th on the list of the largest Japanese pharmaceutical companies. Eisai Co., Ltd. is a Japanese pharmaceutical firm headquartered in Tokyo, Japan. It employs around 10,000 people, with roughly 1,500 working in research. Eisai is traded on the Tokyo Stock Exchange and is a component of the Topix 100 and Nikkei 225 stock indices. Eisai has marketing operations in 19 European nations as well as the Asia-Pacific area.

Eisai Co. Ltd. discovers, develops, manufactures, and markets pharmaceuticals, including prescription drugs, over-the-counter drugs, and generics. Neurology and oncology are two of the company's research franchises. Eisai’s major products include Pariet/AcipHex, Aricept, Halaven, and Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has manufacturing sites in Japan, the United Kingdom, China, and India, as well as laboratories in Japan, the United States, and the United Kingdom; activities in the Americas, Asia and Latin America, EMEA, and Oceania; and overseas sales offices in the United States, Germany, France, China, and South Korea.

Founded: 1941
Headquarters: Tokyo, Japan
Official website: https://www.eisai.com/index.html

Visit website

Shionogi ranks 7th on the list of the largest Japanese pharmaceutical companies. This firm is a Japanese pharmaceutical firm best known for the development of Crestor. Katakana is often used in medical supplies and brand names. Shionogi has been in business since 1878 and was incorporated in 1919. Medicines for hyperlipidemia, antibiotics, and cancer treatments are among the products manufactured. The company is traded on the Tokyo and Osaka stock exchanges and is a component of the Nikkei 225 stock index.'

Shionogi is well-known in Japan as a producer of antimicrobials and antibiotics. Because of antibiotic resistance and the slow growth of the antibiotic market, it has partnered with US-based Schering-Plough (merged in 2009 with Merck & Co.) to become the only marketing agency for its drugs in Japan. Shionogi was an early investor in Ranbaxy Pharmaceuticals, an Indian generic manufacturer. In 2012, the company acquired a stake in ViiV Healthcare, a pharmaceutical firm focused on the development of HIV treatments.

Founded: 1878
Headquarters: Osaka, Japan
Official website: https://www.shionogi.com/global/en/

Visit website

Kyowa Kirin is a global pharmaceutical and biotechnology firm dedicated to enhancing people's health and well-being around the world. Kyowa Kirin was formed in 1949 in Japan and has since grown to become a global corporation with operations in Europe, the Americas, and Asia. The company's primary focus is on the development and commercialization of specialty medicines and biologics in oncology, neurology, nephrology, immunology, and allergies. The objective of the organization is to develop new solutions that solve unmet medical requirements and make a significant difference in the lives of patients.

The research and development efforts of Kyowa Kirin are centered on discovering and developing innovative medicines that meet large unmet medical needs. The company is developing a robust pipeline of pharmaceuticals, including numerous potential first-in-class and best-in-class therapies. In addition to its pharmaceutical and biotechnology operations, Kyowa Kirin has a thriving chemical division that manufactures a variety of fine chemicals and intermediates for use in pharmaceutical, biotechnology, and other sectors.

Founded: 1949

Headquarters: Tokyo, Japan

Official website: https://www.kyowakirin.com/index.html

Visit website

Ono Pharmaceutical Co., Ltd. is one of Japan's largest pharmaceutical corporations. Its headquarters are in Chuo-ku, Osaka, Japan, and it has large plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka, as well as a central research facility in Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's origins may be traced back to 1717, when Ichibei Ono established his pharmaceutical dealer business in Osaka. His company grew and changed names several times before becoming Ono Pharmaceutical Industrial Co., Ltd. in 1948.

Ono Pharmaceutical has three manufacturing facilities: the Joto Product Development Center, the Yamaguchi Plant, and the Fujiyama Plant. It sells products across the Americas, Europe, and Asia. Ono Pharmaceutical is based in Osaka, Japan. Ono has been listed on the Tokyo Stock Exchange since 1963. Its consolidated earnings for the half year ended March 2018 were 16 billion Japanese yen. Nivolumab, a cancer treatment based on the study of Prof.Dr. Tasuku Honjo of Kyoto University, who was awarded the Nobel Prize later that year, is sold by both Ono Pharmaceutical and Bristol-Myers Squibb.

Founded: 1717

Headquarters: Osaka, Japan

Official website: https://www.ono-pharma.com/en

Visit website

Rohto Pharmaceutical Co., Ltd. is an international fast-moving consumer product and pharmaceutical firm headquartered in Osaka's Ikuno-ku with operations in North America, Europe, and Asia. Rohto acquired the Mentholatum Company in 1974. It obtained the trademark rights to Mentholatum in August 1975 and began selling Mentholatum Ointment and Mentholatum Medicated Lip Stick, which proved to be a financial success as the company's revenue climbed to 2.64 billion by April 1981.

The Rohto Group has operations in 15 major markets and distribution agreements in over 150 countries worldwide. They have two manufacturing factories in Japan and six manufacturing plants in the United States, the United Kingdom, China, Vietnam, Hong Kong, and Indonesia. Rohto joined the Indian market in mid-2010, launching operations in the lipcare and skin care segments with their internationally recognized brands, Lipice and Oxy. They also joined the Bangladesh market at the same time. With a strong presence in foreign markets, the company employs over 5,000 people.

Founded: 1949

Headquarters: Osaka, Japan

Official website: https://www.rohto.co.jp/global/

Visit website